Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Current Assets (2018 - 2025)

Historic Current Assets for TransMedics (TMDX) over the last 8 years, with Q3 2025 value amounting to $613.0 million.

  • TransMedics' Current Assets rose 2447.25% to $613.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $613.0 million, marking a year-over-year increase of 2447.25%. This contributed to the annual value of $497.2 million for FY2024, which is 263.15% down from last year.
  • TransMedics' Current Assets amounted to $613.0 million in Q3 2025, which was up 2447.25% from $558.1 million recorded in Q2 2025.
  • Over the past 5 years, TransMedics' Current Assets peaked at $662.7 million during Q2 2023, and registered a low of $95.1 million during Q2 2022.
  • In the last 5 years, TransMedics' Current Assets had a median value of $488.3 million in 2024 and averaged $361.0 million.
  • Its Current Assets has fluctuated over the past 5 years, first crashed by 2957.31% in 2022, then skyrocketed by 59670.29% in 2023.
  • Quarter analysis of 5 years shows TransMedics' Current Assets stood at $118.7 million in 2021, then surged by 112.54% to $252.3 million in 2022, then surged by 102.4% to $510.7 million in 2023, then fell by 2.63% to $497.2 million in 2024, then rose by 23.29% to $613.0 million in 2025.
  • Its Current Assets was $613.0 million in Q3 2025, compared to $558.1 million in Q2 2025 and $505.9 million in Q1 2025.